Abstract
Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary manifestation that has been associated with various diseases. It is a medical emergency that requires prompt diagnosis and aggressive treatment. The clinical manifestations consist of hemoptysis, hypoxia, a drop in the hemoglobin level and new pulmonary infiltrates on chest X-ray. Infrequently, Systemic lupus erythematosus (SLE) and Antiphospholipid syndrome (APS) could be complicated by this severe pulmonary manifestation. The most common histologic lesion in SLE and Antiphospholipid Syndrome is pulmonary capillaritis. Corticosteroids with or without immunosuppressive agents such as cyclophosphamide are the mainstay of the therapy. Plasmapheresis, intravenous immunoglobulin or the newer biologic agents would be considered if there is a persistent lack of clinical response.
Keywords: Systemic lupus erythematosus, diffuse alveolar hemorrhage, antiphospholipid syndrome, pulmonary hemorrhage
Current Respiratory Medicine Reviews
Title: Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome
Volume: 5 Issue: 2
Author(s): Javier A. Cavallasca, Maria del Rosario Maliandi, Diego H. Goffredo and Gustavo G. Nasswetter
Affiliation:
Keywords: Systemic lupus erythematosus, diffuse alveolar hemorrhage, antiphospholipid syndrome, pulmonary hemorrhage
Abstract: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary manifestation that has been associated with various diseases. It is a medical emergency that requires prompt diagnosis and aggressive treatment. The clinical manifestations consist of hemoptysis, hypoxia, a drop in the hemoglobin level and new pulmonary infiltrates on chest X-ray. Infrequently, Systemic lupus erythematosus (SLE) and Antiphospholipid syndrome (APS) could be complicated by this severe pulmonary manifestation. The most common histologic lesion in SLE and Antiphospholipid Syndrome is pulmonary capillaritis. Corticosteroids with or without immunosuppressive agents such as cyclophosphamide are the mainstay of the therapy. Plasmapheresis, intravenous immunoglobulin or the newer biologic agents would be considered if there is a persistent lack of clinical response.
Export Options
About this article
Cite this article as:
Cavallasca A. Javier, Maliandi del Rosario Maria, Goffredo H. Diego and Nasswetter G. Gustavo, Diffuse Alveolar Hemorrhage, A Potentially Life-Threatening Manifestation in Systemic Lupus Erythematosus and the Antiphospholipid Syndrome, Current Respiratory Medicine Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339809788189987
DOI https://dx.doi.org/10.2174/157339809788189987 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imaging Features of Thoracic Manifestations of Behçet’s Disease: Beyond Pulmonary Artery Involvement
Current Medical Imaging Congenital Blood Coagulation Factor XIII Deficiency and Perinatal Management
Current Drug Targets The Biological and Clinical Activity of Anti-Malarial Drugs In Autoimmune Disorders
Current Rheumatology Reviews Positive Aspects, Negative Aspects and Challenges Associated with Stem Cell Therapy for COVID - 19: A Mini-review
Current Stem Cell Research & Therapy Nanoparticulate Drug Delivery Systems for Treatment of Hepatocellular Carcinoma
Current Cancer Therapy Reviews Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal An update on the Management and Treatment of Deep Vein Thrombosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Heparin Induced Thrombocytopenia: Pathogenetic, Clinical, Diagnostic and Therapeutic Aspects
Cardiovascular & Hematological Disorders-Drug Targets Flavonoids and Platelet-Derived Thrombotic Disorders
Current Medicinal Chemistry Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Type 2 Diabetes and Heart Failure: Challenges and Solutions
Current Cardiology Reviews Current and Future Drug Treatments for Glioblastomas
Current Medicinal Chemistry The Influence of Sex Hormones on Pulmonary Vascular Reactivity: Possible Vasodilator Therapies for the Treatment of Pulmonary Hypertension
Current Vascular Pharmacology Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews Is the Carotid Plaque Rupture a Pivotal Event in Stroke Pathogenesis? Update on the Role of the Intraplaque Inflammatory Processes
Current Vascular Pharmacology Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Pulmonary Vascular Function in Insulin Resistance and Diabetes
Current Vascular Pharmacology Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design